Bank Of America Corp Glycomimetics Inc Transaction History

Bank Of America Corp

$1.19 Trillion
Q3 2024

A detailed history of Bank Of America Corp transactions in Glycomimetics Inc stock. As of the latest transaction made, Bank Of America Corp holds 464 shares of GLYC stock, worth $129. This represents 0.0% of its overall portfolio holdings.

Number of Shares

464

Previous 5,402 91.41%

Holding current value

$129

Previous $1,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.16 - $0.32 $790 - $1,580	-4,938 Reduced 91.41%	464 $0
Q2 2024 Aug 14, 2024	SELL	$0.24 - $3.04 $10,929 - $138,444	-45,541 Reduced 89.4%	5,402 $1,000
Q1 2024 May 15, 2024	BUY	$2.55 - $3.49 $78,930 - $108,025	30,953 Added 154.84%	50,943 $152,000
Q4 2023 Feb 14, 2024	BUY	$1.13 - $2.54 $13,436 - $30,203	11,891 Added 146.82%	19,990 $47,000
Q2 2023 Aug 14, 2023	SELL	$1.21 - $2.08 $160 - $276	-133 Reduced 1.62%	8,099 $14,000
Q1 2023 May 12, 2023	BUY	$1.25 - $4.05 $10,142 - $32,861	8,114 Added 6876.27%	8,232 $10,000
Q4 2022 Feb 10, 2023	SELL	$0.57 - $3.03 $5,236 - $27,833	-9,186 Reduced 98.73%	118 $0
Q2 2022 Aug 12, 2022	SELL	$0.54 - $1.15 $3,510 - $7,474	-6,500 Reduced 41.13%	9,304 $5,000
Q1 2022 May 16, 2022	BUY	$1.0 - $1.58 $4,090 - $6,462	4,090 Added 34.92%	15,804 $18,000
Q4 2021 Feb 08, 2022	SELL	$1.44 - $2.14 $4,448 - $6,610	-3,089 Reduced 20.87%	11,714 $17,000
Q3 2021 Nov 15, 2021	SELL	$1.8 - $2.39 $44,287 - $58,803	-24,604 Reduced 62.44%	14,803 $32,000
Q2 2021 Sep 13, 2021	BUY	$2.16 - $3.18 $85,119 - $125,314	39,407 New	39,407 $91,000

Others Institutions Holding GLYC

# of Institutions

Shares Held

17.8M

Call Options Held

Put Options Held

View Full List

About GLYCOMIMETICS INC

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $14.7M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

More about GLYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Glycomimetics Inc Transaction History